View Future GrowthStrategic Partners 過去の業績過去 基準チェック /06Strategic Partnersは78.6%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで13.3%毎年増加している。売上は減少しており、年平均64.6%の割合である。主要情報78.64%収益成長率80.43%EPS成長率Biotechs 業界の成長18.72%収益成長率-64.60%株主資本利益率-4.67%ネット・マージン-277.99%前回の決算情報31 Dec 2025最近の業績更新お知らせ • Dec 06Orphazyme A/S to Report First Half, 2023 Results on Sep 12, 2023Orphazyme A/S announced that they will report first half, 2023 results on Sep 12, 2023すべての更新を表示Recent updatesNew Risk • Apr 04New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.25.4m market cap, or US$3.91m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).お知らせ • Nov 25Strategic Partners A/S, Annual General Meeting, Apr 28, 2026Strategic Partners A/S, Annual General Meeting, Apr 28, 2026, at 10:00 Romance Standard Time.お知らせ • Sep 17Strategic Partners A/S Revises Earnings Guidance for the Fiscal Year 2025Strategic Partners A/S revised earnings guidance for the fiscal year 2025. Based on the first half of the year the company changes its outlook from previously an operating loss in the range of DKK -3 to -4 million to DKK -2 to -3 million.New Risk • Mar 09New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (kr.31.7m market cap, or US$4.61m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.8% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding).New Risk • Feb 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.32.6m market cap, or US$4.57m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).お知らせ • Jan 10Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP).Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. As part of acquisition, 2,327,058 shares were acquired. Stockslatten AB completed the acquisition of 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025.お知らせ • Dec 27Strategic Partners A/S, Annual General Meeting, Mar 26, 2025Strategic Partners A/S, Annual General Meeting, Mar 26, 2025.New Risk • Sep 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.37.5m market cap, or US$5.62m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).New Risk • Aug 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.33.9m market cap, or US$5.07m).Board Change • Mar 11No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Jakob Have is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • Feb 22Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024. Orphazyme informed CombiGene that they in total have acquired approximately 10% of the outstanding shares in CombiGene, which makes Orphazyme one of the larger shareholders in the Company. Orphazyme A/S (CPSE:ORPHA) completed the acquisition of an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024.お知らせ • May 31+ 2 more updatesOrphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFOOrphazyme A/S announced that the board of directors and CFO Anders Fink Vadsholt has entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023.お知らせ • May 18Orphazyme A/S Announces Board ChangesOrphazyme A/S announced that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors. Michael Schlomo Gabriely Hove, Jakob Færch Bendtsen and Jakob Alsted Have were elected as new members of the Board of Directors by the general meeting.お知らせ • Dec 06Orphazyme A/S to Report First Half, 2023 Results on Sep 12, 2023Orphazyme A/S announced that they will report first half, 2023 results on Sep 12, 2023Breakeven Date Change • Mar 01Forecast to breakeven in 2024The 3 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.46.7m in 2024. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 4 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.187.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Price Target Changed • Sep 01Price target decreased to kr.81.00Down from kr.111, the current price target is an average from 6 analysts. New target price is 146% above last closing price of kr.32.98. Stock is down 63% over the past year.Executive Departure • Jul 06Independent Director Martijn Kleijwegt has left the companyOn the 30th of June, Martijn Kleijwegt's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Martijn's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.Executive Departure • Jul 06Independent Director Remi P. Droller has left the companyOn the 30th of June, Remi P. Droller's tenure as Independent Director ended after 6.5 years in the role. We don't have any record of a personal shareholding under Remi P.'s name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.Executive Departure • Jul 06Independent Director Anders Hedegaard has left the companyOn the 30th of June, Anders Hedegaard's tenure as Independent Director ended after 3.6 years in the role. As of March 2021, Anders still personally held 15.68k shares (kr.1.5m worth at the time). A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.Major Estimate Revision • Jun 20Consensus revenue estimates fall to kr.95.0mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from kr.205.5m to kr.95.0m. Forecast losses increased from -kr.7.71 to -kr.9.01 per share. Biotechs industry in Denmark expected to see average net income growth of 0.07% next year. Consensus price target up from kr.111 to kr.127. Share price fell 30% to kr.56.00 over the past week.Price Target Changed • Jun 20Price target increased to kr.127Up from kr.111, the current price target is an average from 3 analysts. New target price is 126% above last closing price of kr.56.00. Stock is down 42% over the past year.Executive Departure • Mar 27Independent Director has left the companyOn the 25th of March, Sten Verland's tenure as Independent Director ended after 10.3 years in the role. We don't have any record of a personal shareholding under Sten's name. A total of 2 executives have left over the last 12 months.分析記事 • Mar 04What Type Of Shareholders Make Up Orphazyme A/S' (CPH:ORPHA) Share Registry?If you want to know who really controls Orphazyme A/S ( CPH:ORPHA ), then you'll have to look at the makeup of its...Price Target Changed • Feb 25Price target lowered to kr.135Down from kr.154, the current price target is an average from 6 analysts. The new target price is 82% above the current share price of kr.74.00. As of last close, the stock is down 25% over the past year.Is New 90 Day High Low • Jan 14New 90-day high: kr.78.30The company is up 13% from its price of kr.69.20 on 16 October 2020. The Danish market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period.Is New 90 Day High Low • Dec 12New 90-day low: kr.56.30The company is down 32% from its price of kr.82.50 on 11 September 2020. The Danish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.分析記事 • Nov 19How Many Orphazyme A/S (CPH:ORPHA) Shares Do Institutions Own?A look at the shareholders of Orphazyme A/S (CPH:ORPHA) can tell us which group is most powerful. Institutions will...Is New 90 Day High Low • Oct 21New 90-day low: kr.66.00The company is down 37% from its price of kr.104 on 22 July 2020. The Danish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Sep 22New 90-day low: kr.80.60The company is down 14% from its price of kr.94.00 on 24 June 2020. The Danish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.収支内訳Strategic Partners の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史CPSE:STRAP 収益、費用、利益 ( )DKK Millions日付収益収益G+A経費研究開発費31 Dec 250-13030 Sep 250-23030 Jun 250-33031 Mar 250-23031 Dec 24003030 Sep 240-62030 Jun 240-112031 Mar 240-197031 Dec 230-2613030 Jun 230-2727031 Mar 230-3234031 Dec 220-3841030 Jun 220-4853031 Mar 220-6368031 Dec 210-7883030 Sep 2112-32720413130 Jun 210-43722619431 Mar 210-53523727831 Dec 200-63324736130 Sep 200-52917733630 Jun 200-42510631131 Mar 200-3817829831 Dec 190-3375128530 Sep 190-3124626630 Jun 190-2864624231 Mar 190-2584121831 Dec 180-2303519730 Sep 180-2063917030 Jun 180-1824114531 Mar 180-1543712131 Dec 170-126339830 Sep 170-104238630 Jun 170-82137531 Mar 170-70106531 Dec 160-58856質の高い収益: STRAPは現在利益が出ていません。利益率の向上: STRAPは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: STRAPは利益を出していないが、過去 5 年間で年間78.6%の割合で損失を削減してきた。成長の加速: STRAPの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: STRAPは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 1.2% ) と比較することは困難です。株主資本利益率高いROE: STRAPは現在利益が出ていないため、自己資本利益率 ( -4.67% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/13 16:57終値2026/07/13 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Strategic Partners A/S 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Tazeen AhmadBofA Global ResearchJacob LademannCarnegie Investment Bank ABThomas BowersDanske Bank4 その他のアナリストを表示
お知らせ • Dec 06Orphazyme A/S to Report First Half, 2023 Results on Sep 12, 2023Orphazyme A/S announced that they will report first half, 2023 results on Sep 12, 2023
New Risk • Apr 04New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.25.4m market cap, or US$3.91m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
お知らせ • Nov 25Strategic Partners A/S, Annual General Meeting, Apr 28, 2026Strategic Partners A/S, Annual General Meeting, Apr 28, 2026, at 10:00 Romance Standard Time.
お知らせ • Sep 17Strategic Partners A/S Revises Earnings Guidance for the Fiscal Year 2025Strategic Partners A/S revised earnings guidance for the fiscal year 2025. Based on the first half of the year the company changes its outlook from previously an operating loss in the range of DKK -3 to -4 million to DKK -2 to -3 million.
New Risk • Mar 09New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (kr.31.7m market cap, or US$4.61m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.8% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding).
New Risk • Feb 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.32.6m market cap, or US$4.57m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).
お知らせ • Jan 10Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP).Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. As part of acquisition, 2,327,058 shares were acquired. Stockslatten AB completed the acquisition of 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025.
お知らせ • Dec 27Strategic Partners A/S, Annual General Meeting, Mar 26, 2025Strategic Partners A/S, Annual General Meeting, Mar 26, 2025.
New Risk • Sep 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.37.5m market cap, or US$5.62m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).
New Risk • Aug 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.33.9m market cap, or US$5.07m).
Board Change • Mar 11No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Jakob Have is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • Feb 22Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024. Orphazyme informed CombiGene that they in total have acquired approximately 10% of the outstanding shares in CombiGene, which makes Orphazyme one of the larger shareholders in the Company. Orphazyme A/S (CPSE:ORPHA) completed the acquisition of an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024.
お知らせ • May 31+ 2 more updatesOrphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFOOrphazyme A/S announced that the board of directors and CFO Anders Fink Vadsholt has entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023.
お知らせ • May 18Orphazyme A/S Announces Board ChangesOrphazyme A/S announced that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors. Michael Schlomo Gabriely Hove, Jakob Færch Bendtsen and Jakob Alsted Have were elected as new members of the Board of Directors by the general meeting.
お知らせ • Dec 06Orphazyme A/S to Report First Half, 2023 Results on Sep 12, 2023Orphazyme A/S announced that they will report first half, 2023 results on Sep 12, 2023
Breakeven Date Change • Mar 01Forecast to breakeven in 2024The 3 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.46.7m in 2024. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 4 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.187.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Price Target Changed • Sep 01Price target decreased to kr.81.00Down from kr.111, the current price target is an average from 6 analysts. New target price is 146% above last closing price of kr.32.98. Stock is down 63% over the past year.
Executive Departure • Jul 06Independent Director Martijn Kleijwegt has left the companyOn the 30th of June, Martijn Kleijwegt's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Martijn's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.
Executive Departure • Jul 06Independent Director Remi P. Droller has left the companyOn the 30th of June, Remi P. Droller's tenure as Independent Director ended after 6.5 years in the role. We don't have any record of a personal shareholding under Remi P.'s name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.
Executive Departure • Jul 06Independent Director Anders Hedegaard has left the companyOn the 30th of June, Anders Hedegaard's tenure as Independent Director ended after 3.6 years in the role. As of March 2021, Anders still personally held 15.68k shares (kr.1.5m worth at the time). A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.
Major Estimate Revision • Jun 20Consensus revenue estimates fall to kr.95.0mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from kr.205.5m to kr.95.0m. Forecast losses increased from -kr.7.71 to -kr.9.01 per share. Biotechs industry in Denmark expected to see average net income growth of 0.07% next year. Consensus price target up from kr.111 to kr.127. Share price fell 30% to kr.56.00 over the past week.
Price Target Changed • Jun 20Price target increased to kr.127Up from kr.111, the current price target is an average from 3 analysts. New target price is 126% above last closing price of kr.56.00. Stock is down 42% over the past year.
Executive Departure • Mar 27Independent Director has left the companyOn the 25th of March, Sten Verland's tenure as Independent Director ended after 10.3 years in the role. We don't have any record of a personal shareholding under Sten's name. A total of 2 executives have left over the last 12 months.
分析記事 • Mar 04What Type Of Shareholders Make Up Orphazyme A/S' (CPH:ORPHA) Share Registry?If you want to know who really controls Orphazyme A/S ( CPH:ORPHA ), then you'll have to look at the makeup of its...
Price Target Changed • Feb 25Price target lowered to kr.135Down from kr.154, the current price target is an average from 6 analysts. The new target price is 82% above the current share price of kr.74.00. As of last close, the stock is down 25% over the past year.
Is New 90 Day High Low • Jan 14New 90-day high: kr.78.30The company is up 13% from its price of kr.69.20 on 16 October 2020. The Danish market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Dec 12New 90-day low: kr.56.30The company is down 32% from its price of kr.82.50 on 11 September 2020. The Danish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
分析記事 • Nov 19How Many Orphazyme A/S (CPH:ORPHA) Shares Do Institutions Own?A look at the shareholders of Orphazyme A/S (CPH:ORPHA) can tell us which group is most powerful. Institutions will...
Is New 90 Day High Low • Oct 21New 90-day low: kr.66.00The company is down 37% from its price of kr.104 on 22 July 2020. The Danish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Sep 22New 90-day low: kr.80.60The company is down 14% from its price of kr.94.00 on 24 June 2020. The Danish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.